Mga Batayang Estadistika
| LEI | 549300VZIH50VYURLQ98 |
| CIK | 1390478 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to SELLAS Life Sciences Group, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-33958 SELLAS Life Sciences Group, Inc. (Exact name of registr |
|
| August 12, 2025 |
As filed with the Securities and Exchange Commission on August 12, 2025 As filed with the Securities and Exchange Commission on August 12, 2025 Registration No. |
|
| August 12, 2025 |
Exhibit 99.1 SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update –Positive IDMC Recommendation to Continue Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in AML Without Modification; Final Analysis Anticipated by Year-end 2025 – –Reported Positive Phase 2 Results of SLS009 in Relapsed/Refractory (r/r) Acute Myeloid Leukemia (AML) with Trial Meeting |
|
| August 12, 2025 |
Amended and Restated 2021 Employee Stock Purchase Plan Exhibit 10.1 SELLAS LIFE SCIENCES GROUP, INC. AMENDED AND RESTATED EMPLOYEE STOCK PURCHASE PLAN Amended and Restated on June 17, 2025 The following constitute the provisions of the Amended and Restated 2021 Employee Stock Purchase Plan (the “Plan”) of Sellas Life Sciences Group, Inc. (the “Company”). 1.Purpose. The purpose of the Plan is to provide Employees of the Company and its Designated Subsi |
|
| August 12, 2025 |
Calculation of Filing Fee Tables S-8 SELLAS Life Sciences Group, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common stock, par value $0.0001 per share 457(a) 800,000 $ 1.58 $ 1,264,000.00 0.0001531 $ 193.52 To |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 12, 2025 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 17, 2025 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or or |
|
| June 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 3, 2025 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or org |
|
| June 6, 2025 |
Exhibit 16.1 June 6, 2025 U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Ladies and Gentlemen: We have read the statements made by the SELLAS Life Sciences Group, Inc. included under Item 4.01 of its Current Report on Form 8-K dated June 3, 2025 to be filed with the Securities and Exchange Commission. We agree with the statements concerning our Firm contained therein |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-33958 SELLAS Life Sciences Group, Inc. (Exact name of regist |
|
| May 13, 2025 |
Exhibit 99.1 SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update –Announced Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 (tambiciclib) in Relapsed/Refractory (r/r) Acute Myeloid Leukemia (AML) Demonstrating 8.9 mOS in AML-MRC and 8.8 mOS in All r/r to Venetoclax-Based Regimens Patients– –SLS009 Shows Promising Efficacy i |
|
| May 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 13, 2025 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or org |
|
| April 23, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definiti |
|
| March 20, 2025 |
Exhibit-10.11 January 22, 2024 Dragan Cicic, M.D. c/o SELLAS Life Sciences Group, Inc. 7 Times Square, Suite 2503 New York, NY 10036 Dear Dragan: The following amends and restates the severance benefits that shall be provided to you in the event of your termination of employment with SELLAS Life Sciences Group, Inc. (the “Company”), on the terms and conditions set forth herein. 1.Severance. (a)Ter |
|
| March 20, 2025 |
Exhibit-10.13 February , 2025 Personal and Confidential Re: Amendment to Change in Control Severance Agreement Dear John Burns: This amendment (this “Amendment”) will serve to implement certain changes to your Change in Control Severance Agreement with SELLAS Life Sciences Group, Inc. (the “Company”), dated December 14, 2021 (the “Agreement”). Capitalized terms used but not defined herein shall ha |
|
| March 20, 2025 |
Code of Business Conduct and Ethics. Exhibit-14.1 SELLAS LIFE SCIENCES GROUP, INC. CODE OF BUSINESS CONDUCT AND ETHICS APPROVED BY THE BOARD OF DIRECTORS AMENDED JUNE 20, 2024 INTRODUCTION SELLAS Life Sciences Group, Inc. (the “Company” or “SELLAS”) is committed to maintaining the highest standards of business conduct and ethics. This Code of Business Conduct and Ethics (the “Code”) reflects the business practices and principles of b |
|
| March 20, 2025 |
Exhibit 99.1 SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update –Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) with Next and Final Analysis Planned Upon Reaching 80 Events, Anticipated in 2025 – –Reported Positive Overall Survival and Overall Response Rate Data from |
|
| March 20, 2025 |
Exhibit-10.9 January 2, 2020 Dragan Cicic, MD Dear Dragan: On behalf of SELLAS Life Sciences Group, Inc. (the “Company”) this letter will confirm our offer of employment to join the Company. The terms are as follows: Employment: You will be employed on a full-time basis as Senior Vice President, Clinical Research & Development, in our New York office, commencing on February 3, 2020. You will repor |
|
| March 20, 2025 |
Exhibit-19.1 SELLAS Life Sciences Group, Inc. Amended and Restated Insider Trading Policy As Amended and Restated by the Board – September 13, 2024 Introduction The federal securities laws prohibit all personnel of SELLAS Life Sciences Group, Inc. (together with its subsidiaries, the “Company”), including any member of the Company’s Board of Directors (a “Director”), Company officer, Company emplo |
|
| March 20, 2025 |
Exhibit-10.12 February , 2025 Personal and Confidential Re: Amendment to Change in Control Severance Agreement Dear Dragan Cicic, M.D.: This amendment (this “Amendment”) will serve to implement certain changes to your Change in Control Severance Agreement with SELLAS Life Sciences Group, Inc. (the “Company”), dated December 14, 2021 (the “Agreement”). Capitalized terms used but not defined herein |
|
| March 20, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 20, 2025 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or o |
|
| March 20, 2025 |
Subsidiaries of the Registrant. Exhibit 21.1 SELLAS Life Sciences Group, Inc. The following is a list of subsidiaries of the Company as of December 31, 2024. SUBSIDIARY STATE OF INCORPORATION OR OTHER (Name under which subsidiary does business) JURISDICTION OF ORGANIZATION Sellas Life Sciences Limited Ireland Sellas Life Sciences Group Ltd. Bermuda SLSG Limited LLC Delaware |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-33 |
|
| January 29, 2025 |
Exhibit 4.1 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK SELLAS Life Sciences Group, Inc. Warrant Shares: Original Issuance Date: , 2025 THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, |
|
| January 29, 2025 |
Exhibit 4.2 WARRANT TO PURCHASE SHARES OF COMMON STOCK SELLAS Life Sciences Group, Inc. Warrant Shares: Original Issuance Date: , 2025 THIS WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or aft |
|
| January 29, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 28, 2025, between SELLAS Life Sciences Group, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and |
|
| January 29, 2025 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-278334 Prospectus Supplement (To prospectus dated May 1, 2024) 8,200,000 Shares of Common Stock Pre-Funded Warrants to Purchase 11,485,040 Shares of Common Stock Warrants to Purchase 19,685,040 Shares of Common Stock We are offering 8,200,000 shares of our common stock, pre-funded warrants to purchase 11,485,040 shares of our common stock (and |
|
| January 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 28, 2025 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or |
|
| January 29, 2025 |
Exhibit 99.1 SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) - SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced |
|
| January 29, 2025 |
Exhibit 1.1 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 and Maxim Group LLC 300 Park Avenue, 16th Floor New York, New York 10022 January 28, 2025 SELLAS Life Sciences Group, Inc. 7 Times Square, Suite 2503 New York, NY 10036 Attention: Angelos M. Stergiou, M.D., ScD h.c., President and Chief Executive Officer Re: Placement Agency Agreemen |
|
| January 23, 2025 |
Exhibit 99.1 SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia 2025-01-23 - REGAL Successfully Passes Event-Driven (60 Deaths) Interim Analysis for Efficacy, Futility, and Safety: The Independent Data Monitoring Committee (IDMC) Recommended Continuation of the Clinical Trial Without Modification - - Based on a R |
|
| January 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 23, 2025 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or |
|
| January 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 10, 2025 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or |
|
| December 10, 2024 |
Exhibit 99.1 SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia - Study Reaches Pre-Specified Threshold of 60 Events (Deaths) Initiating the Interim Analysis – - REGAL Independent Data Monitoring Committee to Perform Interim Analysis in January 2025 - - Company to Host Webcast Call Today at 9:00 am ET NEW YORK, December 10, 2024 (GLOBE NEWSWIRE) |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 10, 2024 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation o |
|
| December 10, 2024 |
C O R P O R A T E P A R T I C I P A N T S Exhibit 99.2 C O R P O R A T E P A R T I C I P A N T S Angelos M. Stergiou, MD, ScD hc, President and Chief Executive Officer, SELLAS Life Science Group P R E S E N T A T I O N Operator Greetings and welcome to the SELLAS Life Sciences Group Corporate Update Call. At this time all participants are in a listen-only mode. Before we begin, please note that today’s call contains forward-looking statem |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-33958 SELLAS Life Sciences Group, Inc. (Exact name of re |
|
| November 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 13, 2024 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation o |
|
| November 13, 2024 |
Exhibit 99.1 SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update - Pre-specified Events to Trigger Interim Analysis of Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Remains on Track for Q4 2024 - - Data from the Phase 2a Trial of SLS009 in Relapsed/Refractory AML After Venetoclax Failure to be Presented at the Upcoming American Societ |
|
| November 8, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* SELLAS Life Sciences Group, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 81642T209 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the |
|
| October 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 3, 2024 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or |
|
| October 4, 2024 |
Exhibit 10.1 TIMES SQUARE TOWER ASSOCIATES LLC c/o Boston Properties Limited Partnership 599 Lexington Avenue, 16th Floor New York, New York 10022 October 2, 2024 Sellas Life Sciences Group, Inc. 7 Times Square, 25th Floor, New York NY 10036 Re: Time Square Tower, 7 Time Square, New York, NY (the “Building”) Ladies and Gentlemen: Reference is hereby made to that certain Sublease dated June |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-33958 SELLAS Life Sciences Group, Inc. (Exact name of registr |
|
| August 13, 2024 |
Exhibit 99.1 SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update - Announced Independent Data Monitoring Committee’s (IDMC) Recommendation to Continue the Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Without Modifications: Interim Analysis Anticipated by Q4 2024 - - Reported Positive Preliminary Data from the Phase 2a Trial of SLS00 |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 13, 2024 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 30, 2024 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or or |
|
| August 1, 2024 |
Exhibit 4.1 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK SELLAS Life Sciences Group, Inc. Warrant Shares: Original Issuance Date: , 2024 THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, |
|
| August 1, 2024 |
Form of Placement Agent Agreement. Exhibit 1.1 Maxim Group LLC 300 Park Avenue New York, NY 10022 July 30, 2024 SELLAS Life Sciences Group, Inc. 7 Times Square, Suite 2503 New York, NY 10036 Attention: Angelos M. Stergiou, M.D., ScD h.c., President and Chief Executive Officer Re: Placement Agency Agreement Dear Dr. Stergiou: Subject to the terms and conditions of this letter agreement (the “Agreement”) between Maxim Group LLC (the |
|
| August 1, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-278334 Prospectus Supplement (To prospectus dated May 1, 2024) 6,370,070 Shares of Common Stock Pre-Funded Warrants to Purchase 9,478,986 Shares of Common Stock Warrants to Purchase 15,849,056 Shares of Common Stock We are offering 6,370,070 shares of our common stock, pre-funded warrants to purchase 9,478,986 shares of our common stock (and th |
|
| August 1, 2024 |
Exhibit 4.2 WARRANT TO PURCHASE SHARES OF COMMON STOCK SELLAS Life Sciences Group, Inc. Warrant Shares: Original Issuance Date: , 2024 THIS WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or aft |
|
| August 1, 2024 |
Exhibit 99.1 SELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to Market NEW YORK, NY July 31, 2024 - SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it has entered into a s |
|
| August 1, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 30, 2024, between SELLAS Life Sciences Group, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and co |
|
| June 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 20, 2024 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or or |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 14, 2024 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or org |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-33958 SELLAS Life Sciences Group, Inc. (Exact name of regist |
|
| May 14, 2024 |
SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update Exhibit 99.1 SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update - Announced Independent Data Monitoring Committee’s (IDMC) Recommendation to Continue the Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Without Modifications: IDMC to Reconvene in June - - Completed Enrollment in Phase 3 REGAL Study of Galinpepimut-S - - Announced Positi |
|
| April 29, 2024 |
As filed with the Securities and Exchange Commission on April 29, 2024 As filed with the Securities and Exchange Commission on April 29, 2024 Registration No. |
|
| April 29, 2024 |
SELLAS Life Sciences Group, Inc. 7 Times Square, Suite 2503 New York, New York 10036 SELLAS Life Sciences Group, Inc. 7 Times Square, Suite 2503 New York, New York 10036 April 29, 2024 Via EDGAR Chris Edwards United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Re: SELLAS Life Sciences Group, Inc. Registration Statement on Form S-3 Filed March 28, 2024 File No. 333-278334 Acceleration Request Dear Mr. Edwards, Pur |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| April 29, 2024 |
Exhibit 4.5 SELLAS LIFE SCIENCES GROUP, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Senior Debt Securities CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a). 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 3 |
|
| April 29, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 29, 2024 |
SELLAS Life Sciences Group, Inc. 7 Times Square, Suite 2503 New York, New York 10036 SELLAS Life Sciences Group, Inc. 7 Times Square, Suite 2503 New York, New York 10036 April 29, 2024 Via EDGAR Chris Edwards United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Re: SELLAS Life Sciences Group, Inc. Registration Statement on Form S-3 Filed March 28, 2024 File No. 333-278337 Acceleration Request Dear Mr. Edwards, Pur |
|
| April 29, 2024 |
Form of Subordinated Indenture. Exhibit 4.6 SELLAS LIFE SCIENCES GROUP, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a). 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.0 |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-33 |
|
| March 28, 2024 |
Exhibit 10.50 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE SELLAS LIFE SCIENCES GROUP, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) THE COMPANY CUSTOMARILY TREATS THAT INFORMATION AS PRIVATE. DATE PROVIDED TO EMPLOYEE: March 8, 2024 CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE This CONFIDENTIAL SEPARATION AGREEM |
|
| March 28, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) SELLAS Life Sciences Group, Inc. |
|
| March 28, 2024 |
Exhibit 10.49 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE SELLAS LIFE SCIENCES GROUP, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) THE COMPANY CUSTOMARILY TREATS THAT INFORMATION AS PRIVATE. February 25, 2022 Robert Francomano [***] Dear Robert: On behalf of SELLAS Life Sciences Group, Inc. (the “Company”) this letter w |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 28, 2024 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or o |
|
| March 28, 2024 |
Separation Agreement, effective as of March 27, 2024, by and between the Registrant and Barbara Wood Exhibit 10.51 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE SELLAS LIFE SCIENCES GROUP, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) THE COMPANY CUSTOMARILY TREATS THAT INFORMATION AS PRIVATE. DATE ORIGINALLY PROVIDED TO EMPLOYEE: March 8, 2024 SEPARATION AGREEMENT AND GENERAL RELEASE This CONFIDENTIAL SEPARATION AGREEMEN |
|
| March 28, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) SELLAS Life Sciences Group, Inc. |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 28, 2024 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or o |
|
| March 28, 2024 |
As filed with the Securities and Exchange Commission on March 28, 2024 As filed with the Securities and Exchange Commission on March 28, 2024 Registration No. |
|
| March 28, 2024 |
As filed with the Securities and Exchange Commission on March 28, 2024 As filed with the Securities and Exchange Commission on March 28, 2024 Registration No. |
|
| March 28, 2024 |
Subsidiaries of the Registrant. Exhibit 21.1 SELLAS Life Sciences Group, Inc. The following is a list of subsidiaries of the Company as of December 31, 2023. SUBSIDIARY STATE OF INCORPORATION OR OTHER (Name under which subsidiary does business) JURISDICTION OF ORGANIZATION Sellas Life Sciences Limited Ireland Sellas Life Sciences Group Ltd. Bermuda SLSG Limited LLC Delaware Apthera, Inc. Delaware |
|
| March 28, 2024 |
Exhibit 99.1 SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update –Announced Phase 2a study of SLS009 in r/r AML Showing 50% Response Rate in the Selected Optimal Dose of 30 mg BIW Exceeding the Targeted 20% and 100% Response Rate in Patients with Identified Biomarkers - –Completed Enrollment in Phase 3 REGAL Study of Galinpepimut-S in Patients with Acute Mye |
|
| March 28, 2024 |
SELLAS Life Sciences Group, Inc. Clawback Policy Exhibit-97 SELLAS LIFE SCIENCES GROUP, INC. Amended and Restated Clawback Policy In the event SELLAS Life Sciences Group, Inc. (the “Company”) is required to prepare an accounting restatement of its financial statements due to the Company’s material noncompliance with any financial reporting requirement under U.S. securities laws, including any required accounting restatement to correct an error i |
|
| March 18, 2024 |
11,000,000 Shares Pre-Funded Warrants to Purchase 2,029,316 Shares Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-255318 Prospectus Supplement (To prospectus dated April 29, 2021) 11,000,000 Shares Pre-Funded Warrants to Purchase 2,029,316 Shares Common Stock We are offering 11,000,000 shares of our common stock and pre-funded warrants to purchase 2,029,316 shares of our common stock (and the shares of common stock issuable from time to time upon exercise |
|
| March 15, 2024 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 15, 2024 |
Exhibit 1.1 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 March 15, 2024 SELLAS Life Sciences Group, Inc. 7 Times Square, Suite 2503 New York, NY 10036 Attention: Angelos M. Stergiou, M.D., ScD h.c., President and Chief Executive Officer Re: Placement Agency Agreement Dear Dr. Stergiou: Subject to the terms and conditions of this letter agreement (th |
|
| March 15, 2024 |
Exhibit 99.1 NEWS RELEASE SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules 3/15/2024 NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) - SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies f |
|
| March 15, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 15, 2024, between SELLAS Life Sciences Group, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and c |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 15, 2024 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or o |
|
| March 15, 2024 |
Exhibit 4.1 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK SELLAS Life Sciences Group, Inc. Warrant Shares: Original Issuance Date: March , 2024 THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 11, 2024 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or o |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 6, 2024 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or or |
|
| March 8, 2024 |
Exhibit 99.1 NEWS RELEASE SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships 3/8/2024 NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) - SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, tod |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 5, 2024 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or or |
|
| February 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 14, 2024 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation o |
|
| February 7, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* SELLAS Life Sciences Group, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 81642T209 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule |
|
| January 19, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) SELLAS Life Sciences Group, Inc. |
|
| January 19, 2024 |
As filed with the Securities and Exchange Commission on January 19, 2024 As filed with the Securities and Exchange Commission on January 19, 2024 Registration No. |
|
| January 8, 2024 |
Form of Placement Agency Agreement entered into in connection with January 2024 Offering Exhibit 1.1 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 January 4, 2024 SELLAS Life Sciences Group, Inc. 7 Times Square, Suite 2503 New York, NY 10036 Attention: Angelos M. Stergiou, M.D., ScD h.c., President and Chief Executive Officer Re: Placement Agency Agreement Dear Dr. Stergiou: Subject to the terms and conditions of this letter agreement (the “Agreemen |
|
| January 8, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 4, 2024, between SELLAS Life Sciences Group, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and |
|
| January 8, 2024 |
Exhibit 4.1 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK SELLAS Life Sciences Group, Inc. Warrant Shares: Original Issuance Date: January , 2024 THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter se |
|
| January 8, 2024 |
Exhibit 4.2 WARRANT TO PURCHASE SHARES OF COMMON STOCK SELLAS Life Sciences Group, Inc. Warrant Shares: Original Issuance Date: Initial Exercise Date: THIS WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at an |
|
| January 8, 2024 |
SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering Exhibit 99.1 NEWS RELEASE SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering 1/4/2024 NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) - SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the pricing of its prev |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 4, 2024 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or |
|
| January 5, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-255318 Prospectus Supplement (To prospectus dated April 29, 2021) 10,130,000 Shares Pre-Funded Warrants to Purchase up to 1,870,000 Shares Warrants to Purchase up to 12,000,000 Shares Common Stock We are offering on a “reasonable best efforts” basis 10,130,000 shares of our common stock, par value $0.0001 per share, pre-funded warrants to purch |
|
| January 4, 2024 |
Subject to completion, dated January 3, 2024 Filed Pursuant to Rule 424(b)(5) Registration No. 333-255318 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities a |
|
| January 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 2, 2024 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 19, 2023 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation o |
|
| December 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 11, 2023 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation o |
|
| December 13, 2023 |
Exhibit 10.1 SECOND AMENDMENT TO SUBLEASE SECOND AMENDMENT TO SUBLEASE (this “Amendment”) made as of the 11th day of December, 2023, and effective as of January 1, 2024 (the “Effective Date”), by and between TIMES SQUARE TOWER ASSOCIATES LLC, a Delaware limited liability company (“Sublandlord”), and SELLAS LIFE SCIENCES GROUP, INC., a New York corporation (“Subtenant”). RECITALS A. Pursuant to a S |
|
| December 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 6, 2023 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-33958 SELLAS Life Sciences Group, Inc. (Exact name of re |
|
| November 9, 2023 |
Exhibit 99.1 SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2023 Financial Results - Phase 3 REGAL Trial of Galinpepimut-S (GPS) on Track to Complete Enrollment ex-China in November 2023 - - Positive Initial Topline Phase 2a Data of SLS009 Reported with First Complete Response Achieved in Acute Myeloid Leukemia (AML) Patient Resistant to Venetoclax Combination Therapies - |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 9, 2023 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or |
|
| November 1, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-255318 Prospectus Supplement (To prospectus dated April 29, 2021) 3,100,000 Shares Pre-Funded Warrants to Purchase 552,300 Shares Warrants to Purchase 3,652,300 Shares Common Stock We are offering 3,100,000 shares of our common stock, pre-funded warrants to purchase 552,300 shares of our common stock (and the shares of common stock issuable fro |
|
| October 31, 2023 |
Form of Placement Agency Agreement Exhibit 1.1 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 and Maxim Group LLC 300 Park Avenue, 16th Floor New York, New York 10022 October 30, 2023 SELLAS Life Sciences Group, Inc. 7 Times Square, Suite 2503 New York, NY 10036 Attention: Angelos M. Stergiou, M.D., ScD h.c., President and Chief Executive Officer Re: Placement Agency Agreement Dear Dr. Stergiou: S |
|
| October 31, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 30, 2023, between SELLAS Life Sciences Group, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and |
|
| October 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 30, 2023 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or |
|
| October 31, 2023 |
Exhibit 4.1 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK SELLAS Life Sciences Group, Inc. Warrant Shares: Original Issuance Date: November 2, 2023 THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the co |
|
| October 31, 2023 |
Exhibit 99.1 SELLAS Life Sciences Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules NEW YORK, NY October 31, 2023 - SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it has entere |
|
| October 31, 2023 |
Exhibit 99.2 NEWS RELEASE SELLAS Life Sciences Receives Fast Track Designation from FDA for SLS009 for Treatment of Relapsed/Refractory Peripheral T-cell Lymphomas 10/30/2023 - SLS009 Demonstrated Promising Efficacy in Phase 1 Study with 36.4% Clinical Response (ORR) in r/r Peripheral T- cell Lymphomas (PTCL); ORR in r/r PTCL Patients with Standard of Care is 25.8% - - Fast Track Designation Accel |
|
| October 31, 2023 |
Exhibit 4.2 WARRANT TO PURCHASE SHARES OF COMMON STOCK SELLAS Life Sciences Group, Inc. Warrant Shares: Original Issuance Date: Initial Exercise Date: THIS WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions h |
|
| October 16, 2023 |
SELLAS Announces Positive Initial Topline Phase 2a Data of SLS009 in Acute Myeloid Leukemia Exhibit 99.1 SELLAS Announces Positive Initial Topline Phase 2a Data of SLS009 in Acute Myeloid Leukemia - SLS009 Is First CDK9 Inhibitor in Combination with AZA/VEN to Achieve Complete Response in AML Patient Resistant to Venetoclax Combination Therapies – - First Patient Enrolled Achieved CR and in Fifth Month of Treatment; Four Patients Continue on Treatment and All Patients Alive – - Anti-leuk |
|
| October 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 16, 2023 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or |
|
| October 13, 2023 |
Exhibit 99.1 SELLAS Life Sciences Provides Update on Phase 3 REGAL Clinical Trial for Galinpepimut-S in Acute Myeloid Leukemia - Enrollment ex-China Expected to be Completed in November 2023 – - Enrollment in China Expected to Commence this Quarter - NEW YORK, NY October 12, 2023 - SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical |
|
| October 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 12, 2023 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-33958 SELLAS Life Sciences Group, Inc. (Exact name of registr |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 10, 2023 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or |
|
| August 10, 2023 |
Exhibit 99.1 SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2023 Financial Results First Patients Dosed in Phase 2a Clinical Trial of SLS009 (formerly GFH009) in Acute Myeloid Leukemia with Topline Data Expected in 4Q 2023 Phase 3 REGAL Study of Galinpepimut-S in Patients with Acute Myeloid Leukemia on Track for Interim Analysis by Late 2023/Early 2024 REGAL Independent D |
|
| August 10, 2023 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE SELLAS LIFE SCIENCES GROUP, INC. |
|
| August 10, 2023 |
2023 Amended and Restated Equity Incentive Plan SELLAS LIFE SCIENCES GROUP, INC. 2023 AMENDED AND RESTATED EQUITY INCENTIVE PLAN Amended and Restated on June 20, 2023 1.DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Sellas Life Sciences Group, Inc. 2023 Amended and Restated Equity Incentive Plan, have the following meanings: Administrator means the Board of Directors, unles |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 20, 2023 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or or |
|
| June 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 30, 2023 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or org |
|
| June 1, 2023 |
C O R P O R A T E P A R T I C I P A N T S Exhibit 99.1 C O R P O R A T E P A R T I C I P A N T S Tara Sobierajski, Senior Manager, Client Success, LifeSci Events Angelos Stergiou, MD, SCD HC, Founder, President and Chief Executive Officer, Sellas Life Sciences Dragan Cicic, MD, Senior Vice President, Clinical Development, Sellas Life Sciences Tapan Kadia, MD, Professor, Department of Leukemia, University of Texas MD Anderson Cancer Center |
|
| May 11, 2023 |
Severance Agreement, dated March 27, 2023, by and between the Registrant and Robert Francomano March 14, 2022 Mr. Robert Francomano c/o SELLAS Life Sciences Group, Inc. 7 Times Square, Suite 2503 New York, NY 10036 Dear Robert: The following severance benefits shall be provided to you in the event of your termination of employment with SELLAS Life Sciences Group, Inc. (the “Company”), on the terms and conditions set forth herein. 1.Severance. (a) Termination Without Cause; For Good Reason. |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 11, 2023 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or org |
|
| May 11, 2023 |
Exhibit 99.1 SELLAS Life Sciences Provides Business Update and Reports First Quarter 2023 Financial Results Phase 1 Study of Novel, Highly Selective CDK9 Inhibitor GFH009 Successfully Completed for Patients with Acute Myeloid Leukemia; 94% of Patients Enrolled to Date Alive and Durable Remission in Patient with Acute Myeloid Leukemia > 6 months Phase 3 REGAL Study of Galinpepimut-S in Patients wit |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-33958 SELLAS Life Sciences Group, Inc. (Exact name of regist |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive |
|
| April 28, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-33 |
|
| March 16, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) SELLAS Life Sciences Group, Inc. |
|
| March 16, 2023 |
Subsidiaries of the Registrant. Exhibit 21.1 SELLAS Life Sciences Group, Inc. The following is a list of subsidiaries of the Company as of December 31, 2022. SUBSIDIARY STATE OF INCORPORATION OR OTHER (Name under which subsidiary does business) JURISDICTION OF ORGANIZATION Sellas Life Sciences Limited Ireland Sellas Life Sciences Group Ltd. Bermuda SLSG Limited LLC Delaware Apthera, Inc. Delaware |
|
| March 16, 2023 |
Exhibit 99.1 SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update Phase 3 REGAL GPS AML Study on Track for Interim Analysis by Late 2023/Early 2024 Ongoing Phase 1 Study of CDK9 Inhibitor Suggests Broad Therapeutic Window and High Potential for Both Monotherapy and Combination Treatment $20 Million of Gross Proceeds from Capital Raise in February 2023 Adds to |
|
| March 16, 2023 |
Side Letter Agreement, dated December 5, 2022, by and between the Registrant and 3D Medicines Inc. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE SELLAS LIFE SCIENCES GROUP, INC. |
|
| March 16, 2023 |
As filed with the Securities and Exchange Commission on March 16, 2023 S-8 1 tm239579d1s8.htm FORM S-8 As filed with the Securities and Exchange Commission on March 16, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 20-8099512 (State or other jurisdiction o |
|
| March 16, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 16, 2023 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or o |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 10, 2023 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or o |
|
| March 1, 2023 |
Form of Amendment to Common Stock Purchase Warrant Exhibit 10.1 SELLAS LIFE SCIENCES GROUP, INC. AMENDMENT TO THE COMMON STOCK PURCHASE WARRANT This Amendment to the Common Stock Purchase Warrant (this “Amendment”), dated as of February 28, 2023, is being entered into by and among SELLAS Life Sciences Group, Inc., a Delaware corporation (the “Company”), and the Holder identified on the signature pages hereto (the “Holder”). WHEREAS, the Holder is |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 28, 2023 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation o |
|
| February 24, 2023 |
Exhibit 99.1 The registrant is filing this Exhibit 99.1 for the purpose of incorporating the information set forth herein by reference into the registration statement on Form S-3 (File No. 333-255318) that was filed by the registrant with the Securities and Exchange Commission on April 16, 2021 and was declared effective on April 29, 2021. The following table sets forth the estimated costs and exp |
|
| February 24, 2023 |
Exhibit 4.1 FORM OF WARRANT COMMON STOCK PURCHASE WARRANT SELLAS Life Sciences Group, Inc. Warrant Shares: Issue Date: February , 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue D |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 23, 2023 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation o |
|
| February 24, 2023 |
SELLAS Life Sciences Announces Pricing of $20.0 Million Underwritten Public Offering Exhibit 99.2 SELLAS Life Sciences Announces Pricing of $20.0 Million Underwritten Public Offering NEW YORK, February 24, 2023 – SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the pricing of its previously announced under |
|
| February 24, 2023 |
Exhibit 1.1 SELLAS LIFE SCIENCES GROUP, INC. 7,220,217 Shares of Common Stock (par value $0.0001 per share) Warrants to Purchase 7,220,217 Shares of Common Stock Underwriting Agreement February 23, 2023 Cantor Fitzgerald & Co. As Representative of the several Underwriters listed in Schedule A hereto c/o Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: SELLAS Life Sc |
|
| February 24, 2023 |
7,220,217 Shares Warrants to Purchase up to 7,220,217 Shares Common stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-255318 Prospectus Supplement (To prospectus dated April 29, 2021) 7,220,217 Shares Warrants to Purchase up to 7,220,217 Shares Common stock We are offering 7,220,217 shares of our common stock and warrants to purchase up to 7,220,217 shares of our common stock (and the shares of common stock issuable from time to time upon exercise of such warr |
|
| February 23, 2023 |
Subject to completion, dated February 23, 2023 Filed Pursuant to Rule 424(b)(5) Registration No. 333-255318 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities a |
|
| February 23, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 23, 2023 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation o |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 2, 2023 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or |
|
| December 13, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 13, 2022 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation o |
|
| December 13, 2022 |
Exhibit 99.1 SELLAS Announces Positive Phase 1 Data with CDK9 Inhibitor GFH009 Monotherapy in Patients with Relapsed/Refractory Hematologic Malignancies GFH009 is First CDK9 Inhibitor Monotherapy to Achieve Compete Response in Acute Myeloid Leukemia Anticancer Effects Observed Across Multiple Dose Levels in Both Acute Myeloid Leukemia and Lymphoma Patients No Dose Limiting Toxicities Observed at A |
|
| November 15, 2022 |
C O R P O R A T E P A R T I C I P A N T S Exhibit 99.1 C O R P O R A T E P A R T I C I P A N T S Allison Soss, Investor Relations, KCSA Strategic Communications Angelos Stergiou, MD, ScD hc, Founder, President & Chief Executive Officer, SELLAS Life Sciences Group M. Yair Levy, MD, Director of Hematologic Malignancies, Baylor University Medical Center Dragan Cicic, M.D. - Senior Vice President, Clinical Development, SELLAS Life Sciences P |
|
| November 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 14, 2022 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation o |
|
| November 14, 2022 |
Exhibit 99.1 SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2022 Financial Results – Cash Position of $21.3 Million as of September 30, 2022 – – Hosting Phase 3 REGAL Study Update Webcast Today at 8:30 a.m. ET – NEW YORK, November 14, 2022 – SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused |
|
| November 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 14, 2022 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation o |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-33958 SELLAS Life Sciences Group, Inc. (Exact name of re |
|
| November 14, 2022 |
Exhibit 99.2 SELLAS Life Sciences Announces Update on Phase 3 REGAL Clinical Trial Evaluating Lead Asset, Galinpepimut-S, in Acute Myeloid Leukemia – Overall Survival Observed in Pooled Patient Data to Date Leads to Changes in Statistical Analysis Plan: Interim Analysis Now at 60 Events and Final Analysis Now at 80 Events – – 3D Medicines to Participate in REGAL Clinical Trial, Which Will Trigger |
|
| September 16, 2022 |
Investor Symposium on Galinpepimut - S September 15, 2022 NASDAQ: SLS Exhibit 99.1 Investor Symposium on Galinpepimut - S September 15, 2022 NASDAQ: SLS NASDAQ: SLS Forward Looking Statements This presentation contains forward - looking statements. Such forward - looking statements can be identified by the use of the word s ?expect,? ?believe,? ?will,? ?anticipate,? ?estimate,? ?plan,? ?project? and other words of similar import. The forward - looking statements in |
|
| September 16, 2022 |
C O R P O R A T E P A R T I C I P A N T S Exhibit 99.2 C O R P O R A T E P A R T I C I P A N T S Allison Soss, Investor Relations, KCSA Strategic Communications Dr. Angelos Stergiou, Founder, President & Chief Executive Officer Robert Francomano, Chief Commercial Officer P R E S E N T A T I O N Operator Greetings. Welcome to SELLAS Life Sciences Investor Symposium on GPS. Please note, this conference is being recorded. I would now like to |
|
| September 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 15, 2022 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation |
|
| August 16, 2022 |
Exhibit 99.1 SELLAS Life Sciences? Announces Election of Katherine Bach Kalin to its Board of Directors - Ms. Kalin Joins the Board with Decades of Life Sciences and Healthcare Industry Experience - NEW YORK, August 16, 2022 ? SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (?SELLAS?? or the ?Company?), a late-stage clinical biopharmaceutical company focused on the development of novel therapies fo |
|
| August 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 13, 2022 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or |
|
| August 11, 2022 |
Exhibit 99.1 SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2022 Financial Results ? Reported Encouraging Updated Data in Q2 from Two Clinical Trials of Galinpepimut-S (GPS) in Combination with Checkpoint Inhibitors ? ? Provides Clinical Update for GFH009 Program ? ? Cash Position of $27.0 million as of June 30, 2022 ? ? To Host Virtual Investor Symposium on GPS on Septem |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-33958 SELLAS Life Sciences Group, Inc. (Exact name of registr |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 11, 2022 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or |
|
| June 9, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 8, 2022 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or org |
|
| May 12, 2022 |
Exhibit 99.1 SELLAS Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update ?Enhanced Pipeline with New Asset, GFH009, an In-licensed Next-Generation, Highly Selective CDK9 Inhibitor ? ?$25 Million of Gross Proceeds from Capital Raise in April 2022 and $1 Million Milestone Payment Received in May 2022 Add to Cash Balance of $14.3 Million as of March 31, 2022 ? NEW Y |
|
| May 12, 2022 |
As filed with the Securities and Exchange Commission on May 12, 2022 As filed with the Securities and Exchange Commission on May 12, 2022 Registration No. |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-33958 SELLAS Life Sciences Group, Inc. (Exact name of regist |
|
| May 12, 2022 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE SELLAS LIFE SCIENCES GROUP, INC. |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 12, 2022 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or org |
|
| May 12, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) SELLAS Life Sciences Group, Inc. |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 25, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549? SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ? |
|
| April 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 6, 2022 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or or |
|
| April 6, 2022 |
Exhibit 99.1 SELLAS Life Sciences Group, Inc. — Business Update and First Quarter 2022 Highlights Call, April 6, 2022 CORPORATE PARTICIPANTS Angelos M. Stergiou, CEO CONFERENCE CALL PARTICIPANTS Allison Soss, KCSA Strategic Communications - Allison Soss Okay, let us begin with the forward looking statements: Good morning, everyone, and welcome to SELLAS shareholder update call. I am Allison Soss, |
|
| April 1, 2022 |
Exhibit 99.1 The registrant is filing this Exhibit 99.1 for the purpose of incorporating the information set forth herein by reference into the registration statement on Form S-3 (File No. 333-255318) that was filed by the registrant with the Securities and Exchange Commission on April 16, 2021 and was declared effective on April 29, 2021. The following table sets forth the estimated costs and exp |
|
| April 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 31, 2022 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or o |
|
| April 1, 2022 |
Exhibit 1.1 SELLAS Life Sciences Group, Inc. (a Delaware corporation) 4,629,630 Shares of Common Stock and Warrants to Purchase 4,629,630 Shares of Common Stock UNDERWRITING AGREEMENT March 31, 2022 SVB Securities LLC and Cantor Fitzgerald & Co. as Representatives of the several Underwriters c/o SVB Securities LLC 1301 Avenue of the Americas, 12th Floor New York, NY 10019 c/o Cantor Fitzgerald & C |
|
| April 1, 2022 |
SELLAS Life Sciences Announces Pricing of $25.0 Million Underwritten Public Offering Exhibit 99.2 SELLAS Life Sciences Announces Pricing of $25.0 Million Underwritten Public Offering NEW YORK, March 31, 2022 ? SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (?SELLAS? or the ?Company?), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the pricing of its previously announced underwri |
|
| April 1, 2022 |
4,629,630 Shares Warrants to Purchase up to 4,629,630 Shares Common stock 424B5 1 tm2211298d1424b5.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-255318 Prospectus Supplement (To prospectus dated April 29, 2021) 4,629,630 Shares Warrants to Purchase up to 4,629,630 Shares Common stock We are offering 4,629,630 shares of our common stock and warrants to purchase up to 4,629,630 shares of our common stock (and the shares of common stock issuable from time |
|
| April 1, 2022 |
Exhibit 4.1 FORM OF WARRANT COMMON STOCK PURCHASE WARRANT SELLAS Life Sciences Group, Inc. Warrant Shares: Issue Date: April , 2022 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date |
|
| March 31, 2022 |
Exhibit 10.36 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [***] has been excluded from the exhibit, because it is both not material and is the type of information that the Registrant treats as private or confidential. FIRST AMENDMENT TO SUBLEASE THIS FIRST AMENDMENT TO SUBLEASE ("First Amendment" or "this Amendment") is made as of this 6th day of D |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-33 |
|
| March 31, 2022 |
Entry into a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 30, 2022 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or o |
|
| March 31, 2022 |
Subsidiaries of the Registrant Exhibit 21.1 SELLAS Life Sciences Group, Inc. The following is a list of subsidiaries of the Company as of December 31, 2021. SUBSIDIARY STATE OF INCORPORATION OR OTHER (Name under which subsidiary does business) JURISDICTION OF ORGANIZATION Sellas Life Sciences Limited Ireland Sellas Life Sciences Group Ltd. Bermuda SLSG Limited LLC Delaware Apthera, Inc. Delaware |
|
| March 31, 2022 |
Subject to completion, dated March 31, 2022 Filed Pursuant to Rule 424(b)(5) Registration No. 333-255318 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities a |
|
| December 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 14, 2021 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation o |
|
| December 16, 2021 |
Exhibit 10.1 December 14, 2021 Dragan Cicic, M.D. c/o SELLAS Life Sciences Group, Inc. 7 Times Square, Suite 2503 New York, NY 10036 Dear Dragan: The following severance benefits shall be provided to you in the event of the termination of your employment with SELLAS Life Sciences Group, Inc. (the ?Company?) or its successor following a Change in Control Event (as hereinafter defined), on the terms |
|
| November 12, 2021 |
SELLAS Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update Exhibit 99.1 SELLAS Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update NEW YORK, November 12, 2021 ? SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (?SELLAS? or the ?Company?), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today reported its financial results for the quarter |
|
| November 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 12, 2021 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation o |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-33958 SELLAS Life Sciences Group, Inc. (Exact name of re |
|
| September 24, 2021 |
SELLAS Life Sciences Announces Settlement of Derivative Litigation Exhibit 99.1 SELLAS Life Sciences Announces Settlement of Derivative Litigation NEW YORK, September 23, 2021 - SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the ?Company?), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that on September 10, 2021 the United States District Court for |
|
| September 24, 2021 |
UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY Exhibit 99.2 UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY LARRY KELLER, Derivatively on Behalf of SELLAS LIFE SCIENCES GROUP, INC. (f/k/a GALENA BIOPHARMA, INC.), Plaintiff, vs. WILLIAM L. ASHTON, RICHARD CHIN, IRVING M. EINHORN, STEPHEN GALLIKER, MARY ANN GRAY, SANFORD J. HILLSBERG, RUDOLPH NISI, Defendants, and, SELLAS LIFE SCIENCES GROUP, INC. (f/k/a GALENA BIOPHARMA, Inc.), Nominal Defe |
|
| September 24, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 23, 2021 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation |
|
| September 24, 2021 |
UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY Exhibit 99.3 UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY LARRY KELLER, Derivatively on Behalf of SELLAS LIFE SCIENCES GROUP, INC. (f/k/a GALENA BIOPHARMA, INC.), Plaintiff, vs. WILLIAM L. ASHTON, RICHARD CHIN, IRVING M. EINHORN, STEPHEN GALLIKER, MARY ANN GRAY, SANFORD J. HILLSBERG, RUDOLPH NISI, Defendants, and, SELLAS LIFE SCIENCES GROUP, INC. (f/k/a GALENA BIOPHARMA, Inc.), Nominal Defe |
|
| August 13, 2021 |
As filed with the Securities and Exchange Commission on August 13, 2021 As filed with the Securities and Exchange Commission on August 13, 2021 Registration No. |
|
| August 12, 2021 |
Exhibit 99.1 SELLAS Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update Reported Promising Updated Clinical Data in Ongoing Clinical Trials of Galinpepimut-S (GPS) in Combination with PD-1 Inhibitors for Malignant Pleural Mesothelioma (MPM) and WT1+ Advanced Ovarian Cancer Recently Published Outcomes Data for Acute Myeloid Leukemia (AML) Patients Highlights Con |
|
| August 12, 2021 |
2021 Employee Stock Purchase Plan. Exhibit 10.1 SELLAS LIFE SCIENCES GROUP, INC. EMPLOYEE STOCK PURCHASE PLAN The following constitute the provisions of the 2021 Employee Stock Purchase Plan (the ?Plan?) of Sellas Life Sciences Group, Inc. (the ?Company?). 1.Purpose. The purpose of the Plan is to provide Employees of the Company and its Designated Subsidiaries with an opportunity to purchase Common Stock of the Company. It is the i |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 12, 2021 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-33958 SELLAS Life Sciences Group, Inc. (Exact name of registr |
|
| July 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 6, 2021 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or org |
|
| June 14, 2021 |
SELLAS Life Sciences Group, Inc. Shareholder Update Call June 3, 2021 Exhibit 99.1 SELLAS Life Sciences Group, Inc. Shareholder Update Call June 3, 2021 SELLAS Life Sciences Group, Inc. ? Shareholder Update Call, June 3, 2021 C O R P O R A T E P A R T I C I P A N T S Allison Soss, Investor Relations Dr. Angelos Stergiou, Founder, President & Chief Executive Officer C O N F E R E N C E C A L L P A R T I C I P A N T S Jason McCarthy, Maxim Group Jim Malloy (phon), All |
|
| June 14, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 3, 2021 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or o |
|
| June 9, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 8, 2021 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or org |
|
| June 4, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 3, 2021 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or org |
|
| June 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| June 4, 2021 |
SELLAS Life Sciences Group, Inc. – Shareholder Update Call, June 3, 2021 Exhibit 99.1 SELLAS Life Sciences Group, Inc. ? Shareholder Update Call, June 3, 2021 C O R P O R A T E P A R T I C I P A N T S Allison Soss, Investor Relations Dr. Angelos Stergiou, Founder, President & Chief Executive Officer C O N F E R E N C E C A L L P A R T I C I P A N T S Jason McCarthy, Maxim Group Jim Malloy (phon), Alliance Global Partners P R E S E N T A T I O N Operator Greetings and w |
|
| June 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 1, 2021 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or org |
|
| May 13, 2021 |
Exhibit 99.1 SELLAS Life Sciences Reports First Quarter 2021 Financial Results and Provides Business Update Received $1.0 Million Milestone Payment and Recognized $5.7 Million of License Revenue Under Exclusive License Agreement with 3D Medicines for Development and Commercialization of Galinpepimut-S (GPS) in Greater China National Ethics Committee Approval for GPS Phase 3 REGAL Study Received in |
|
| May 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 13, 2021 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or org |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-33958 SELLAS Life Sciences Group, Inc. (Exact name of regist |
|
| April 27, 2021 |
SELLAS Life Sciences Group, Inc. 7 Times Square, Suite 2503 New York, New York 10036 April 27, 2021 SELLAS Life Sciences Group, Inc. 7 Times Square, Suite 2503 New York, New York 10036 April 27, 2021 Via EDGAR Margaret Schwartz United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Re: SELLAS Life Sciences Group, Inc. Registration Statement on Form S-3 File No. 333-255318 Acceleration Request Dear Ms. Schwartz, Pursuant to Rule 46 |
|
| April 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| April 21, 2021 |
United States securities and exchange commission logo April 21, 2021 Angelos M. Stergiou, M.D., ScD h.c President and Chief Executive Officer SELLAS Life Sciences Group, Inc. 7 Times Square, Suite 2503 New York, NY 10036 Re: SELLAS Life Sciences Group, Inc. Registration Statement on Form S-3 Filed April 16, 2021 File No. 333-255318 Dear Dr. Stergiou: This is to advise you that we have not reviewed |
|
| April 16, 2021 |
As filed with the Securities and Exchange Commission on April 16, 2021 Registration No. |
|
| April 16, 2021 |
Exhibit 1.2 Execution Version SELLAS LIFE SCIENCES GROUP, INC. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement April 16, 2021 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: SELLAS Life Sciences Group, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cantor Fitzgerald & Co |
|
| March 23, 2021 |
Exhibit 10.50 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE SELLAS LIFE SCIENCES GROUP, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO SELLAS LIFE SCIENCES GROUP, INC. IF PUBLICLY DISCLOSED. SELLAS Life Sciences Group, Inc. Times Square Tower 7 Times Square, Suite 2503 New York, New Yo |
|
| March 23, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 23, 2021 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or o |
|
| March 23, 2021 |
Subsidiaries of the Registrant Exhibit 21.1 SELLAS Life Sciences Group, Inc. The following is a list of subsidiaries of the Company as of December 31, 2020. SUBSIDIARY STATE OF INCORPORATION OR OTHER (Name under which subsidiary does business) JURISDICTION OF ORGANIZATION Sellas Life Sciences Limited Ireland Sellas Life Sciences Group Ltd. Bermuda SLSG Limited LLC Delaware Apthera, Inc. Delaware |
|
| March 23, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-33 |
|
| March 23, 2021 |
EXHIBIT 99.1 SELLAS Life Sciences Reports Full Year 2020 Financial Results and Provides Business Update Entered into Exclusive License Agreement, with $7.5 Million Upfront License Fee and Potential to Receive up to an Additional $194.5 Million, with 3D Medicines for Development and Commercialization of Galinpepimut-S in China; Additional $1 Million Milestone Triggered in February 2021 Strengthened |
|
| February 16, 2021 |
CUSIP No: 81642T209 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* SELLAS Life Sciences Group, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 81642T209 ( |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No.1 )* SELLAS Life Sciences Group, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 81842T100 (CUSIP Number) December 31, 2020 (Date of Event which requires Filing of th |
|
| February 12, 2021 |
JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. |
|
| February 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 29, 2021 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or |
|
| January 28, 2021 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE SELLAS LIFE SCIENCES GROUP, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO SELLAS LIFE SCIENCES GROUP, INC. IF PUBLICLY DISCLOSED. Exclusive License Agreement by and between SELLAS LIFE SCIENCES GROUP, Inc., SLSG Limited, LLC, |
|
| January 28, 2021 |
Financial Statements and Exhibits - FORM 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 7, 2020 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation |
|
| January 14, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 14, 2021 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or |
|
| January 14, 2021 |
Exhibit 99.1 SELLAS Life Sciences Highlights 2020 Business and Clinical Progress and 2021 Milestones - Phase 3 REGAL Study of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Patients Underway in United States and Europe - - License Agreement with 3D Medicines for Development and Commercialization of GPS in China Initiates Commercialization Strategy for GPS - - Balance Sheet Significantly Stre |
|
| December 23, 2020 |
Financial Statements and Exhibits, Other Events 8-K 1 tm2039231d18k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 21, 2020 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or othe |
|
| December 23, 2020 |
Exhibit 99.1 SELLAS Announces Promising Initial Clinical Data for Galinpepimut-S (GPS) in Combination with Checkpoint Inhibitors in Two Solid Tumor Indications - Early Data from Study of GPS in Combination with Keytruda® in Patients with Advanced WT1(+) Ovarian Cancer Shows Disease Control Rate of 87.5% at a Median Follow-up of 9.4 Weeks and 100% Progression Free Survival at 6 Weeks - - Early Data |
|
| December 14, 2020 |
SELLAS LIFE SCIENCES GROUP, INC. 2,320,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-233869 PROSPECTUS SUPPLEMENT (To Prospectus dated October 11, 2019) SELLAS LIFE SCIENCES GROUP, INC. 2,320,000 Shares of Common Stock We are offering 2,320,000 shares of our common stock, par value $0.0001 per share (the “Common Stock”). Our Common Stock is listed on The Nasdaq Capital Market, or Nasdaq, under the symbol “SLS.” The la |
|
| December 14, 2020 |
SELLAS Announces Pricing of $16.2 Million Registered Direct Offering Exhibit 99.1 SELLAS Announces Pricing of $16.2 Million Registered Direct Offering NEW YORK, December 13, 2020 - SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced that it has entered into a share purchase agreem |
|
| December 14, 2020 |
Share Purchase Agreement dated December 13, 2020 between the Registrant and certain investors Exhibit 10.1 Execution Version SHARE PURCHASE AGREEMENT This Share Purchase Agreement (this “Agreement”) is dated as of December 13, 2020, between SELLAS Life Sciences Group, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).” WHEREAS, subject to the |
|
| December 14, 2020 |
Form of Placement Agent Agreement. Exhibit 1.1 SUBJECT TO LEGAL REVIEW AND COMMITMENT COMMITTEE APPROVAL CONFIDENTIAL December 11, 2020 SELLAS Life Sciences Group, Inc. 7 Times Square Suite 2503 New York, NY 10036 Ladies and Gentlemen: This letter (the “Agreement”) constitutes the agreement between SELLAS Life Sciences Group, Inc. (the “Company”) and Maxim Group, LLC (“Maxim” or the “Lead Manager”), that Maxim shall serve as the ex |
|
| December 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 11, 2020 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation o |
|
| December 14, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment No. 1 Under the Securities Exchange Act of 1934 SELLAS Life Sciences Group, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 81642T100 (CUSIP Number) December 11, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| December 10, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 7, 2020 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or |
|
| December 10, 2020 |
Exhibit 99.1 SELLAS Life Sciences and 3D Medicines Announce Exclusive License Agreement for Development and Commercialization of Galinpepimut-S (GPS) and GPS+ in Greater China - SELLAS to Potentially Receive Up To $202 Million, Inclusive of $7.5 Million Upfront License Fee and $8 Million Near-term Milestones, plus Tiered Royalties - - 3D Medicines to Lead Clinical Development and Commercialization |
|
| November 13, 2020 |
EXHIBIT 99.1 SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2020 Financial Results - Received IMPD Approval to Commence Enrollment in France for Pivotal Phase 3 Study of Galinpepimut-S in Acute Myeloid Leukemia patients - - Strengthened Balance Sheet During Quarter with $9.2 million Financing - NEW YORK, November 13, 2020 - SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (" |
|
| November 13, 2020 |
Exhibit 10.3 FIRST AMENDMENT TO AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT This First Amendment to Amended and Restated Exclusive License Agreement (this ?Amendment?), effective as of September 29, 2020 (the ?Effective Date?), is entered into by and between SLSG Limited LLC (together with its affiliates, hereinafter collectively ?Company?), a Delaware limited liability company with a place o |
|
| November 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-33958 SELLAS Life Sciences Group, Inc. (Exact name of re |
